title: Novel Glutamatergic Treatments for Severe Mood Disorders.
abstract: All currently approved antidepressant medications for major depressive disorder (MDD) and bipolar disorder act primarily on the monoaminergic system and have varying affinities for serotonergic, norepinephrine-ergic, and/or dopaminergic receptors. Unfortunately, these drugs are only effective in approximately two-thirds of patients. Glutamate is the major excitatory neurotransmitter in the central nervous system, and the glutamatergic system has been implicated in the pathophysiology of MDD. Here, we review the putative involvement of the glutamate receptor subtypes-N-methyl-D-aspartate (NMDA), α-amino-3-hydroxyl-5-methyl-4-isoxazoleproprionic acid (AMPA), kainate, and the group I, II, and III metabotropic glutamate receptors (mGluRs)-in the development of novel and more effective treatments for MDD as well as preclinical and clinical trials of drugs targeting these receptors. The rapid and robust antidepressant effects of ketamine-an NMDA receptor antagonist-have been consistently replicated in multiple trials. Other glutamatergic drugs have been investigated with varying success. Here, we highlight some of the most interesting results, including: 1) repeated oral, intramuscular, and sublingual ketamine appears to be less robustly effective than intravenous ketamine, but also causes fewer significant adverse effects; 2) the glycine partial agonist GLYX-13 appears to be effective both as monotherapy and adjunctive treatment in the treatment of MDD. An oral analogue, NRX-1074, is currently under investigation; and 3) mGluR modulators targeting mGluR5 have demonstrated convincing preclinical results.
authors.affiliation: Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD U.S.A., 20892.
authors.forename: Minkyung
authors.initials: M
authors.lastname: Park
authors.affiliation: Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD U.S.A., 20892.
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Niciu
authors.affiliation: Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD U.S.A., 20892.
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Zarate
keywords: N-methyl-D-aspartate (NMDA); antagonist; glutamate; metabotropic positive allosteric modulator; mood disorders; negative allosteric modulator
references.citation: Nat Neurosci. 1999 Mar;2(3):234-40
references.pmid: 10195215
references.citation: Neuron. 1999 Jul;23(3):583-92
references.pmid: 10433269
references.citation: Biol Psychiatry. 2000 Feb 15;47(4):351-4
references.pmid: 10686270
references.citation: Br J Pharmacol. 2001 Apr;132(7):1423-30
references.pmid: 11264235
references.citation: Neuroscience. 2001;106(3):481-503
references.pmid: 11591452
references.citation: Curr Drug Targets CNS Neurol Disord. 2002 Apr;1(2):191-213
references.pmid: 12769627
references.citation: JAMA. 2003 Jun 18;289(23):3095-105
references.pmid: 12813115
references.citation: Eur J Neurosci. 2003 Jun;17(11):2409-17
references.pmid: 12814372
references.citation: Ann Pharmacother. 2003 Dec;37(12):1891-9
references.pmid: 14632596
references.citation: Int J Neuropsychopharmacol. 2004 Mar;7(1):1-8
references.pmid: 14720317
references.citation: Neuropharmacology. 2004 Mar;46(4):457-67
references.pmid: 14975669
references.citation: Brain Res Mol Brain Res. 2005 May 20;136(1-2):29-37
references.pmid: 15893584
references.citation: Pharmacol Biochem Behav. 2005 Aug;81(4):901-6
references.pmid: 16040106
references.citation: Nature. 2005 Nov 10;438(7065):185-92
references.pmid: 16281028
references.citation: Am J Psychiatry. 2006 Jan;163(1):153-5
references.pmid: 16390905
references.citation: J Neurosci. 2006 Apr 26;26(17):4559-66
references.pmid: 16641235
references.citation: J Affect Disord. 2006 Jul;93(1-3):239-43
references.pmid: 16677714
references.citation: Pharmacol Rep. 2006 May-Jun;58(3):427-30
references.pmid: 16845218
references.citation: Arch Gen Psychiatry. 2006 Aug;63(8):856-64
references.pmid: 16894061
references.citation: CNS Neurol Disord Drug Targets. 2007 Apr;6(2):117-26
references.pmid: 17430149
references.citation: Curr Drug Targets. 2007 May;8(5):603-20
references.pmid: 17504104
references.citation: Biol Psychiatry. 2008 Feb 15;63(4):349-52
references.pmid: 17643398
references.citation: Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15537-42
references.pmid: 17881561
references.citation: Behav Pharmacol. 2007 Dec;18(8):731-43
references.pmid: 17989511
references.citation: Aust N Z J Psychiatry. 2008 Sep;42(9):751-62
references.pmid: 18696279
references.citation: Anesthesiology. 2008 Oct;109(4):707-22
references.pmid: 18813051
references.citation: J Clin Psychopharmacol. 2008 Dec;28(6):631-7
references.pmid: 19011431
references.citation: Nature. 2009 Jun 4;459(7247):703-7
references.pmid: 19404260
references.citation: Exp Brain Res. 2009 Dec;199(3-4):203-34
references.pmid: 19777221
references.citation: Pharmacopsychiatry. 2010 Jan;43(1):33-5
references.pmid: 20013614
references.citation: Br J Pharmacol. 2010 May;160(2):181-90
references.pmid: 20423333
references.citation: J Pharmacol Exp Ther. 2010 Sep 1;334(3):1066-74
references.pmid: 20562216
references.citation: J Palliat Med. 2010 Jul;13(7):903-8
references.pmid: 20636166
references.citation: Neurosci Lett. 2010 Sep 27;482(2):137-41
references.pmid: 20638442
references.citation: Anesthesiology. 2010 Sep;113(3):678-84
references.pmid: 20693870
references.citation: Pharmacol Rep. 2010 Nov-Dec;62(6):1186-90
references.pmid: 21273676
references.citation: Biol Psychiatry. 2011 Apr 15;69(8):754-61
references.pmid: 21292242
references.citation: Biol Psychiatry. 2011 Aug 15;70(4):e9-10; author reply e11-2
references.pmid: 21481846
references.citation: Am J Psychiatry. 2011 Jul;168(7):727-34
references.pmid: 21498461
references.citation: J Pharmacol Exp Ther. 2011 Jul;338(1):345-52
references.pmid: 21508084
references.citation: Eur J Pharmacol. 1990 Aug 21;185(1):1-10
references.pmid: 2171955
references.citation: Nature. 2011 Jul 06;475(7354):27-30
references.pmid: 21734685
references.citation: Pharmacol Biochem Behav. 2012 Feb;100(4):656-64
references.pmid: 21889952
references.citation: Eur Neuropsychopharmacol. 2011 Sep;21(9):655-79
references.pmid: 21896369
references.citation: J Neurogenet. 2011 Dec;25(4):152-66
references.pmid: 22091727
references.citation: Int J Neuropsychopharmacol. 2012 May;15(4):429-34
references.pmid: 22114864
references.citation: Pharmacol Biochem Behav. 2012 Mar;101(1):35-40
references.pmid: 22138407
references.citation: J Affect Disord. 2012 May;138(3):295-300
references.pmid: 22326841
references.citation: J Clin Psychopharmacol. 2012 Aug;32(4):551-7
references.pmid: 22722512
references.citation: Biol Psychiatry. 2013 Aug 15;74(4):250-6
references.pmid: 22840761
references.citation: Drugs R D. 2012 Sep 1;12(3):127-39
references.pmid: 22852579
references.citation: Am J Psychiatry. 2012 Aug;169(8):868-9
references.pmid: 22854933
references.citation: Neuroscience. 2012 Oct 25;223:219-24
references.pmid: 22890078
references.citation: Neuropharmacology. 2013 Jan;64:337-46
references.pmid: 22992331
references.citation: Int J Neuropsychopharmacol. 2013 Apr;16(3):501-6
references.pmid: 23174090
references.citation: Biol Psychiatry. 2013 Aug 15;74(4):257-64
references.pmid: 23206319
references.citation: J Psychopharmacol. 2013 May;27(5):444-50
references.pmid: 23428794
references.citation: Biol Psychiatry. 2013 Jun 15;73(12):1125-32
references.pmid: 23453290
references.citation: Neurosci Lett. 2013 Jun 24;546:6-10
references.pmid: 23643996
references.citation: Int J Neuropsychopharmacol. 2013 Oct;16(9):2111-7
references.pmid: 23683309
references.citation: J Palliat Med. 2013 Aug;16(8):958-65
references.pmid: 23805864
references.citation: Am J Psychiatry. 2013 Oct;170(10):1134-42
references.pmid: 23982301
references.citation: Psychopharmacology (Berl). 2014 Feb;231(4):685-93
references.pmid: 24114429
references.citation: Mol Psychiatry. 2014 Sep;19(9):978-85
references.pmid: 24126931
references.citation: J Clin Psychiatry. 2013 Oct;74(10):966-73
references.pmid: 24229746
references.citation: Expert Opin Investig Drugs. 2014 Feb;23(2):243-54
references.pmid: 24251380
references.citation: Neuropsychopharmacology. 2014 Jan;39(1):233
references.pmid: 24317309
references.citation: Front Pharmacol. 2013 Dec 27;4:161
references.pmid: 24409146
references.citation: Aust N Z J Psychiatry. 2014 Jul;48(7):686
references.pmid: 24452289
references.citation: Neuropharmacology. 2014 Jul;82:59-68
references.pmid: 24631968
references.citation: J Psychopharmacol. 2014 Jun;28(6):536-44
references.pmid: 24699062
references.citation: Biol Psychiatry. 2014 Dec 15;76(12):970-6
references.pmid: 24821196
references.citation: Behav Brain Res. 2014 Sep 1;271:111-5
references.pmid: 24909673
references.citation: World J Biol Psychiatry. 2014 Sep;15(7):579-84
references.pmid: 24910102
references.citation: Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8649-54
references.pmid: 24912158
references.citation: Int J Neuropsychopharmacol. 2014 Nov;17(11):1805-13
references.pmid: 24963561
references.citation: J Affect Disord. 2014;167:333-5
references.pmid: 25016490
references.citation: Behav Brain Res. 2014 Oct 15;273:23-33
references.pmid: 25043733
references.citation: Neuropsychopharmacology. 2015 Jan;40(2):259-67
references.pmid: 25257213
references.citation: Elife. 2014 Oct 23;3:e03581
references.pmid: 25340958
references.citation: Curr Opin Pharmacol. 2015 Feb;20:95-101
references.pmid: 25529199
references.citation: Curr Opin Neurobiol. 2015 Feb;30:139-43
references.pmid: 25562451
references.citation: Biol Psychiatry. 2015 Jul 1;78(1):10-18
references.pmid: 25577164
references.citation: J Clin Psychiatry. 2015 Jan;76(1):e91-7
references.pmid: 25650685
references.citation: Curr Mol Med. 2015;15(3):206-21
references.pmid: 25817855
references.citation: Ther Adv Chronic Dis. 2015 May;6(3):97-114
references.pmid: 25954495
references.citation: Neuropsychopharmacology. 2017 Mar;42(4):844-853
references.pmid: 27681442
references.citation: Brain Res. 1994 Dec 15;666(2):189-94
references.pmid: 7533633
references.citation: J Neurosci. 1996 Mar 15;16(6):2044-56
references.pmid: 8604049